Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The analysis of the financial leverage and debt ratios over the presented periods indicates several noteworthy trends and shifts in the company's financial structure and risk profile.
- Debt to Equity Ratio
- The debt to equity ratio exhibits a consistent downward trend from 0.08 in the first quarter of 2020, gradually declining to 0.01 by the first quarter of 2025. This indicates a steady reduction in the company’s reliance on debt relative to equity, reflecting a strengthening equity base or reduced debt levels over time.
- Debt to Equity Ratio (Including Operating Lease Liability)
- Accounting for operating lease liabilities, the debt to equity ratio starts at 0.08 in early 2020, fluctuates moderately, and shows a noticeable increase during late 2024, peaking around 0.11 before slightly tapering to 0.10 in early 2025. This suggests that when operating leases are factored into liabilities, the perceived leverage is higher and exhibits volatility towards the end of the timeline.
- Debt to Capital Ratio
- This ratio follows a similar declining pattern as the debt to equity ratio, moving from 0.08 to 0.01 over the period, reinforcing the reduction in debt burden relative to total capital. This decline signals improved capital structure health and potentially lower financial risk.
- Debt to Capital Ratio (Including Operating Lease Liability)
- When including operating leases, the debt to capital ratio begins at 0.08 and decreases steadily until mid-2024, but then rises sharply towards late 2024 and early 2025 to around 0.09–0.10. This rise aligns with the pattern seen in the inclusive debt to equity ratio, suggesting increased liabilities classified under leases impacting the overall capital structure during this time.
- Debt to Assets Ratio
- The debt to assets ratio decreases marginally from 0.06 in early 2020 to near 0 by the first quarter of 2025, reflecting a diminishing portion of assets financed through debt. This trend supports the notion of reduced leverage and potentially stronger asset backing of the company’s obligations.
- Debt to Assets Ratio (Including Operating Lease Liability)
- Including operating lease liabilities, this ratio mirrors the previous ratios' behavior, with a stable decrease until mid-2024 followed by an upward spike in the last few quarters. The ratio increasing to approximately 0.07-0.08 near the end of the period highlights the significant impact of lease obligations on total assets financing.
- Financial Leverage
- Financial leverage remains relatively stable around the 1.3 mark across the timeline, showing minor fluctuations within 1.28 to 1.42. The leverage slightly rises approaching late 2024, likely corresponding with the noted upticks in lease-adjusted debt ratios, indicating a higher total asset to equity ratio and an increased use of debt or liabilities to finance assets.
- Interest Coverage Ratio
- Interest coverage ratios, available from late 2020 onwards, demonstrate a generally strong capacity to cover interest expenses, rising steadily from approximately 54.6 to a peak around 111.6 in mid-2024. This denotes improved earnings relative to interest costs and a lower risk of default on debt service. However, a dramatic drop occurs in the last quarter of 2024 and first quarter of 2025, turning negative to -11.94. This sharp decline may indicate a significant reduction in earnings or an increase in interest expense, suggesting potential financial distress or extraordinary charges affecting profitability.
Overall, the data reveals a company that has been steadily reducing its traditional debt levels relative to equity, capital, and assets over the observed period. The inclusion of operating lease liabilities uncovers underlying volatility and an increased liability profile towards the end of the timeline. Despite generally strong interest coverage through most of the period, the sudden negative turn in the latest quarters flags a need for caution and further investigation into the causes behind this shift.
Debt Ratios
Coverage Ratios
Debt to Equity
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Long-term finance lease liabilities | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to equity1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
-
The total debt has exhibited a clear and consistent downward trend over the observed period. Starting from approximately $533 million in March 2020, the debt level decreased gradually each quarter. By the end of 2023, total debt had reduced to around $376 million, continuing the decline into 2024 and reaching approximately $111 million by March 2025. This steady reduction suggests active debt management or repayment efforts, significantly lowering the company's leverage.
- Shareholders’ Equity
-
Shareholders’ equity shows a general upward trajectory from March 2020 through most of 2023, increasing from about $6.5 billion to over $17.5 billion by December 2023. This growth demonstrates strengthening equity bases, potentially driven by retained earnings, capital increases, or asset appreciation. However, in early 2024 there is a notable drop to approximately $14.8 billion in June, followed by a recovery back to around $16.5 billion by March 2025. This volatility in 2024 likely reflects specific financial events affecting equity.
- Debt to Equity Ratio
-
The debt to equity ratio shows a declining pattern throughout the entire period. Beginning at 0.08 in March 2020, it progressively decreased each quarter, reaching a very low ratio of 0.01 by early 2024 and maintaining that level through March 2025. This indicates a substantial reduction in financial leverage relative to equity, suggesting that the company is lowering its reliance on debt financing and strengthening its capital structure.
- Summary Insights
-
The financial data reflects an improving capital structure over the examined timeframe, marked by decreasing debt levels and expanding shareholders’ equity. The company's consistent efforts to reduce debt have effectively lowered leverage risks. Despite an isolated equity downturn in mid-2024, the overall equity base has grown substantially from 2020 onwards. The combination of these trends implies enhanced financial stability and potentially increased capacity for investment or resilience against market volatility.
Debt to Equity (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =
The financial data reveals several key trends concerning the company's leverage and equity position over the analyzed quarters.
- Total Debt (including operating lease liability)
-
Total debt showed moderate fluctuations from 2020 through early 2023, generally declining from approximately $532.9 million in March 2020 to around $724.7 million by December 2023. A notable increase occurred beginning in the first quarter of 2024, with debt rising sharply from $721.3 million in March 2024 to approximately $1.65 billion by March 2025, indicating a significant increase in leverage during this most recent period.
- Shareholders’ Equity
-
Shareholders' equity demonstrated consistent growth from roughly $6.46 billion at the beginning of 2020, advancing steadily each quarter to reach a peak of about $18.58 billion in June 2024. However, in the succeeding quarters through March 2025, equity exhibited some retracement, decreasing to approximately $16.50 billion. This pattern suggests overall strong capital accumulation with some recent contraction.
- Debt to Equity Ratio (including operating lease liability)
-
The debt to equity ratio remained relatively low and stable, fluctuating between 0.04 and 0.1 for most of the period, reflecting conservative leverage levels in relation to equity. Notably, starting in the first quarter of 2024, the ratio increased from 0.04 to approximately 0.11 by September 2024, and slightly decreased to 0.10 by March 2025. This ratio movement corresponds with the significant debt increase and equity decline observed in the same timeframe, implying a shift towards higher leverage and potential changes in the company's capital structure strategy.
In summary, the company maintained a strong equity base with relatively low debt levels for several years, supporting a low debt-to-equity ratio indicative of conservative financial management. However, the data from 2024 onward reveals a marked increase in total debt alongside a slight reduction in equity, resulting in increased leverage. This shift may reflect strategic financing decisions or changes in operational financing requirements and warrants further investigation to assess its impact on financial stability and risk profile.
Debt to Capital
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Long-term finance lease liabilities | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||||
Total capital | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to capital1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
- Total Debt Trend
-
The total debt shows a general downward trend over the analyzed periods. Starting at approximately $533 million in March 2020, debt levels gradually declined to around $346 million by June 2024. A significant drop is noted between September 2024 and December 2024, where the debt decreased sharply from $346.6 million to $114 million, continuing to decline modestly thereafter to about $111.4 million by March 2025. This pattern indicates a strong deleveraging effort or repayment of obligations especially in the most recent quarters.
- Total Capital Trend
-
Total capital demonstrated an overall increasing trajectory from March 2020 through September 2024, rising from approximately $6.99 billion to a peak of about $18.9 billion. Notably, after reaching this peak in June 2024, there was a marked decrease in total capital to $15.1 billion by September 2024. However, total capital partially recovered towards the end of the period, ending at roughly $16.6 billion in March 2025. This trend reflects substantial growth with a temporary contraction in late 2024, which could suggest asset sales, revaluation, or other capital adjustments.
- Debt to Capital Ratio
-
The debt to capital ratio exhibits a consistent decline throughout the entire period. Beginning at 0.08 in March 2020, the ratio declined steadily to 0.01 by late 2024 and remained at this level into early 2025. This reduction indicates an improving capital structure with decreasing reliance on debt financing relative to total capital, aligning with observed reductions in total debt and growth in capital base in earlier periods. The very low ratio towards the end of the timeline suggests a strong equity or non-debt based capitalization profile.
- Overall Financial Position Insights
-
The analysis reveals a company that has actively managed to reduce its debt burden substantially while expanding its capital base over most of the analyzed periods. The sharp decrease in debt in late 2024, coupled with a reduction in total capital, may hint at strategic financial restructuring. The declining debt to capital ratio throughout underscores enhanced financial stability and reduced leverage, indicating a potential increase in financial flexibility and reduced credit risk.
Debt to Capital (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
- Total Debt (including operating lease liability)
- The total debt level exhibited moderate fluctuations from March 2020 through December 2021, initially increasing from approximately $533 million to a peak near $889 million in December 2020, followed by a gradual decline to about $725 million by December 2021. This downward trend continued until March 2024, reaching a low around $721 million. However, a significant increase occurred in the subsequent periods, with debt sharply rising to approximately $933 million by June 2024 and then doubling to over $1.7 billion by September 2024. The level remains elevated through March 2025 at about $1.65 billion, indicating a substantial increase in leverage or funding needs in the most recent quarters.
- Total Capital (including operating lease liability)
- Total capital showed consistent growth from March 2020 until December 2023, increasing steadily from around $7.0 billion to nearly $18.3 billion. This reflects an expansion of the company’s capital base over these years. An interruption in the growth pattern is observed in March 2024, where total capital declined notably to approximately $15.7 billion, before recovering and increasing again to about $18.1 billion by March 2025. This volatility suggests significant capital structure adjustments or fluctuations in equity or other capital components occurring in 2024.
- Debt to Capital Ratio (including operating lease liability)
- The debt to capital ratio remained relatively low and stable, fluctuating between 0.04 and 0.09 throughout most of the observed period from 2020 to early 2024. This indicates a conservative leverage position for much of the timeframe. Notably, there is a marked increase in this ratio starting from June 2024, rising sharply from 0.04 to 0.10 in September 2024. Although it slightly decreases to 0.09 by March 2025, the leverage level remains elevated compared to prior years, consistent with the rise in total debt observed during the same period. Overall, the trend suggests increased leveraging risk or financing activity toward the end of the timeline.
- Summary Insights
- The data reveals a generally growing capital structure alongside low leverage ratios until early 2024. Significant shifts occur thereafter, with a pronounced increase in total debt and debt to capital ratio, accompanied by temporary volatility in total capital. These changes may reflect strategic financing decisions, increased borrowing to support operations or investments, or changes in market or business conditions requiring heightened leverage. Monitoring the sustainability of this increased debt level and its impact on financial stability will be important going forward.
Debt to Assets
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Long-term finance lease liabilities | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to assets1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt shows a consistent downward trend over the analyzed periods. Starting from approximately $533 million in the first quarter of 2020, debt modestly fluctuates in the initial quarters but begins a steady decline from 2022 onwards. By the first quarter of 2025, total debt has decreased sharply to around $111 million, representing a significant reduction in the company's debt obligations over the observed timeframe.
- Total Assets
- Total assets demonstrate a strong upward trend throughout the period. Beginning at about $8.9 billion in early 2020, the asset base expands steadily, reaching a peak near $24 billion by the third quarter of 2024. Even though there is a slight decrease between the second quarter of 2024 and the first quarter of 2025, total assets remain substantially higher overall. The increase in assets indicates ongoing growth or acquisition activity, enhancing the company's resource base.
- Debt to Assets Ratio
- The debt to assets ratio declines consistently, reflecting the combined effect of decreasing debt and rising assets. From an initial ratio of 0.06 in early 2020, the ratio gradually falls to virtually zero by the first quarter of 2025. This trend highlights a marked improvement in the financial leverage position, suggesting enhanced solvency and reduced financial risk over time.
Debt to Assets (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
The financial data reflects the trends in total debt, total assets, and the debt-to-assets ratio over a five-year period from March 2020 to March 2025.
- Total Debt (including operating lease liability)
- The total debt figures exhibit moderate fluctuation up to the end of 2023, with values generally decreasing from $532.952 million in March 2020 to $724.7 million in December 2023. However, a notable increase occurs beginning in the first quarter of 2024, with total debt escalating sharply to $933.4 million in March 2024 and soaring to approximately $1.65 billion by the end of 2024 and $1.65 billion in early 2025. This sharp rise suggests significant new borrowing or lease liabilities during this recent period.
- Total Assets
- Total assets have shown a consistent growth trend throughout the observed timeframe. Starting at about $8.89 billion in March 2020, the asset base incrementally expanded to $22.73 billion by December 2023. In 2024, there is an initially observed decrease in total assets to approximately $20.13 billion in the first half of 2024, followed by recovery and growth to about $22.83 billion by March 2025. The overall trajectory reflects expansion in the company's asset base despite the temporary decline in early 2024.
- Debt to Assets Ratio (including operating lease liability)
- The debt to assets ratio has remained relatively low and stable through most of the period, ranging from 0.03 to 0.08, indicating conservative leverage relative to asset value. The ratio peaks at 0.08 during the end of 2020 and again in early 2024, coinciding with the periods of increased total debt relative to assets. Notably, there is a dip in leverage from 2021 to 2023, with ratios declining to as low as 0.03, reflecting either reduced debt, increased assets, or both. The sudden increase in leverage in 2024 aligns with the surge in debt and slight asset contraction, suggesting a strategic or necessary increase in debt funding during this period.
In summary, the company maintained a stable leverage position for several years with growing assets and relatively controlled debt levels. However, the sharp increase in total debt and corresponding rise in leverage ratios starting early 2024 implies a significant shift, potentially relating to capital raising, investment, or other financial strategies impacting the debt structure. The temporary decline in assets during this period may accentuate the increase in leverage, highlighting a period of financial adjustment or structural change.
Financial Leverage
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Financial leverage1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals notable trends in total assets, shareholders’ equity, and financial leverage over the observed periods.
- Total Assets
- The total assets exhibit a consistent upward trajectory from March 31, 2020, through March 31, 2025. Beginning at approximately $8.89 billion, the assets increase steadily each quarter, reaching a peak near $23 billion by the end of the reported period. There is a marked and continuous growth, especially notable in the transitions between the years 2021 and 2023. Despite a slight dip from June 30, 2024, to September 30, 2024, the overall trend remains strongly positive, indicating sustained expansion in asset base.
- Shareholders’ Equity
- Shareholders’ equity similarly demonstrates strong growth over the reported timeline, rising from roughly $6.46 billion in early 2020 to about $16.5 billion by March 31, 2025. The growth pattern is fairly steady with incremental quarterly increases. However, a temporary decrease is observed between June 30, 2024, and September 30, 2024, where equity declines from approximately $18.5 billion to $15 billion before recovering in subsequent quarters. This fluctuation may point to internal events influencing equity such as share repurchases, dividends, or adjustments to retained earnings. Overall, the increasing equity corroborates the growth in total assets and suggests strengthening capitalization.
- Financial Leverage
- Financial leverage ratios exhibit relative stability throughout the period, fluctuating mostly between 1.28 and 1.42. Beginning at 1.38 in March 2020, the ratio slightly decreases over time, reaching lows around 1.28 to 1.29 during 2022 and early 2023, implying a modest reduction in leverage and potentially a stronger equity position relative to liabilities. However, in 2024, the financial leverage ratio rises again, peaking near 1.42 before settling back near 1.39 at the end of the analyzed period. These movements indicate variations in the balance between debt and equity financing, with a general pattern that suggests management is maintaining moderate leverage without drastic shifts.
In summary, the data reflects a company experiencing robust asset and equity growth, underpinned by relatively stable financial leverage. While minor fluctuations occur, particularly in mid-2024, the overarching trend is one of strengthening financial position and controlled leverage expansion.
Interest Coverage
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||
Add: Income tax expense | ||||||||||||||||||||||||||||
Add: Interest expense | ||||||||||||||||||||||||||||
Earnings before interest and tax (EBIT) | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Interest coverage1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Interest coverage
= (EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024
+ EBITQ2 2024)
÷ (Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024
+ Interest expenseQ2 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The earnings before interest and tax (EBIT) exhibit notable volatility over the analyzed periods. Initially, EBIT showed an upward trend, increasing from $671,670 thousand in March 2020 to a peak of $1,192,100 thousand in September 2022. However, the figure experienced considerable fluctuations subsequently, with a sharp decline to negative $3,381,300 thousand in June 2024, followed by a partial recovery to $733,400 thousand by March 2025. This pattern indicates periods of strong operational performance interrupted by substantial downturns, which may suggest episodic challenges or extraordinary items affecting earnings.
Interest expense decreased gradually over time, starting at $14,136 thousand in March 2020 and declining steadily to $2,800 thousand by March 2025. This consistent reduction suggests effective management of debt levels or refinancing at more favorable terms, resulting in lower interest obligations.
The interest coverage ratio, which measures the ability to meet interest payments from EBIT, generally improved markedly from values around 54.6 and 55.95 in the mid-2020 quarters to a peak exceeding 111 in the fourth quarter of 2023. This improvement reflects enhanced financial stability and stronger earnings relative to interest expense. However, there is a significant drop in coverage ratio to 6.14 and further down to negative values by December 2024 and March 2025, respectively, corresponding with the interim sharp decline in EBIT. Such decline implies a reduced capacity to cover interest expenses during these periods, indicating potential financial distress or non-recurring losses impacting operating earnings.
Overall, the company demonstrated effective control over interest costs and improvement in interest coverage for the majority of the timeframe. Nonetheless, the latter part of the series reveals considerable earnings instability that adversely affects the interest coverage. This mixed performance underscores the need for further examination of the underlying causes behind the EBIT fluctuations to assess sustainability and risk.